A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT07010263 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

560

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: AK112
OTHER: Placebo

Sponsor

Akeso